ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

Subgroup analysis revealed a pronounced effect among patients receiving MAC. In this cohort, 6-month grade 2-4 GFS was 35.7% with placebo vs 60.7% with ustekinumab (OR 2.78 for failure; 80% CI, 1.19-6 ...

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) ...

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 – CABOMETYX ...

A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...

Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer. Subgroup OS HR (95% CI) OS p-value ...

The MarketWatch News Department was not involved in the creation of this content. EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and ...

On 30 September 2025, at the European Respiratory Society (ERS) Conference, held in Amsterdam, the Netherlands, Insmed presented results from a subgroup analysis from the Phase III ASPEN study ...

This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...